Wistar blueprints big expansion

The Wistar Institute plans to knock down part of its cancer research center to make way for a major new addition. Blueprints call for a seven-story research center, the first major expansion to be planned at the site since 1975. Story

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.